-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The throat is the fortress of the human body.
Common throat diseases include sore throat, hoarse voice, cough or dryness and other symptoms
.
Throat disease is a very common disease in clinical practice, especially in winter, when throat disease occurs frequently
.
Recently, as the temperature has gradually dropped, the weather has become dry, and various throat diseases have begun to occur at a high rate.
Therefore, throat medication has also attracted people's attention
.
It is understood that throat diseases usually recur and are difficult to cure.
Therefore, throat medication has always been valued by the pharmaceutical industry in the market
.
For example, according to relevant data, in 2020, the sales of terminal throat Chinese patent medicines in physical pharmacies in Chinese cities will exceed 4.
9 billion yuan.
It is expected that in 2021, sales in this market will increase by 1.
1% year-on-year, hovering at the 5 billion mark
.
In addition, data shows that in 2020, 10 varieties of Chinese patent medicines for throat sales exceed 100 million yuan
.
In the field of throat Chinese patent medicines, representative companies include Yangzijiang Pharmaceutical, Guilin Sanjin, Golden Throat, Guilong Pharmaceutical, and Jiangzhong Pharmaceutical
.
Among them, Yangzijiang Pharmaceutical's throat Chinese patent medicine market in 2020 has a market share of more than 20%.
Its Lanqin oral liquid is popular among consumers in the field of pharyngitis medication
.
Guilin Sanjin throat Chinese patent medicines mainly include Guilin Watermelon Cream and Watermelon Cream Moisturizing Throat Tablets, and data shows that their market share in throat Chinese patent medicines is showing an upward trend
.
For example, according to the company's semi-annual report, the company's semi-annual operating income in 2021 increased by 16.
97% year-on-year to 870 million yuan; net profit attributable to shareholders of listed companies increased by 2.
46% year-on-year to 240 million yuan
.
Jiangzhong Compound Cao Shan Shan Lotion combines ancient Chinese medicine culture and modern scientific research.
It has the effects of clearing wind and heat, reducing swelling and pain, and clearing throat.
It can effectively prevent and treat dry and itchy throat, and it is also very effective for upper respiratory tract infections.
Good effect, often used to treat diseases such as Fengreganmao and periodontitis
.
The "Manyan Shuning" series of products produced by Guilong Pharmaceutical, a professional medicine for the treatment of chronic pharyngitis, effectively help consumers relieve their pain
.
It is reported that Guilong Pharmaceutical has formed a greater influence in the field of throat health by virtue of its product advantages such as "Manyan Shuning"
.
However, it is worth noting that the recent throat drug company Golden Throat suddenly announced its delisting, which aroused the market's attention
.
Data show that Golden Throat’s representative products Golden Throat Lozenge and Golden Throat Lozenge have begun to face sales ceilings in recent years
.
For example, according to data from Minai.
com, the sales of Golden Throat Throat in physical pharmacies in Chinese cities have been rising all the way, exceeding 400 million yuan in 2016 and 500 million yuan in 2019, but sales in 2020 will decline by nearly 15%, and it is expected to be 2021 Sales also failed to exceed 500 million yuan
.
Golden Voice said that the privatization is a good opportunity for shareholders to realize their investment
.
The company needs a clear revitalization plan, and this will require substantial investment, which can only be achieved through privatization and the introduction of external capital from investment professionals
.
After privatization, Golden Voice will carry out business transformation and look for opportunities for a comeback
.
Nowadays, with the acceleration of the pace of life and work, as well as the influence of many factors such as poor air quality in cities and poor living habits, the incidence of various throat diseases is rising rapidly
.
Data show that the incidence of chronic pharyngitis in urban population in China accounts for 10%-12% of all pharyngeal diseases, and the incidence rate is as high as 60%-70%
.
Therefore, it is still very important to strengthen the R&D and production of drugs in the throat field, and the throat drug market still has a broad space for development
.
Common throat diseases include sore throat, hoarse voice, cough or dryness and other symptoms
.
Throat disease is a very common disease in clinical practice, especially in winter, when throat disease occurs frequently
.
Recently, as the temperature has gradually dropped, the weather has become dry, and various throat diseases have begun to occur at a high rate.
Therefore, throat medication has also attracted people's attention
.
It is understood that throat diseases usually recur and are difficult to cure.
Therefore, throat medication has always been valued by the pharmaceutical industry in the market
.
For example, according to relevant data, in 2020, the sales of terminal throat Chinese patent medicines in physical pharmacies in Chinese cities will exceed 4.
9 billion yuan.
It is expected that in 2021, sales in this market will increase by 1.
1% year-on-year, hovering at the 5 billion mark
.
In addition, data shows that in 2020, 10 varieties of Chinese patent medicines for throat sales exceed 100 million yuan
.
In the field of throat Chinese patent medicines, representative companies include Yangzijiang Pharmaceutical, Guilin Sanjin, Golden Throat, Guilong Pharmaceutical, and Jiangzhong Pharmaceutical
.
Among them, Yangzijiang Pharmaceutical's throat Chinese patent medicine market in 2020 has a market share of more than 20%.
Its Lanqin oral liquid is popular among consumers in the field of pharyngitis medication
.
Guilin Sanjin throat Chinese patent medicines mainly include Guilin Watermelon Cream and Watermelon Cream Moisturizing Throat Tablets, and data shows that their market share in throat Chinese patent medicines is showing an upward trend
.
For example, according to the company's semi-annual report, the company's semi-annual operating income in 2021 increased by 16.
97% year-on-year to 870 million yuan; net profit attributable to shareholders of listed companies increased by 2.
46% year-on-year to 240 million yuan
.
Jiangzhong Compound Cao Shan Shan Lotion combines ancient Chinese medicine culture and modern scientific research.
It has the effects of clearing wind and heat, reducing swelling and pain, and clearing throat.
It can effectively prevent and treat dry and itchy throat, and it is also very effective for upper respiratory tract infections.
Good effect, often used to treat diseases such as Fengreganmao and periodontitis
.
The "Manyan Shuning" series of products produced by Guilong Pharmaceutical, a professional medicine for the treatment of chronic pharyngitis, effectively help consumers relieve their pain
.
It is reported that Guilong Pharmaceutical has formed a greater influence in the field of throat health by virtue of its product advantages such as "Manyan Shuning"
.
However, it is worth noting that the recent throat drug company Golden Throat suddenly announced its delisting, which aroused the market's attention
.
Data show that Golden Throat’s representative products Golden Throat Lozenge and Golden Throat Lozenge have begun to face sales ceilings in recent years
.
For example, according to data from Minai.
com, the sales of Golden Throat Throat in physical pharmacies in Chinese cities have been rising all the way, exceeding 400 million yuan in 2016 and 500 million yuan in 2019, but sales in 2020 will decline by nearly 15%, and it is expected to be 2021 Sales also failed to exceed 500 million yuan
.
Golden Voice said that the privatization is a good opportunity for shareholders to realize their investment
.
The company needs a clear revitalization plan, and this will require substantial investment, which can only be achieved through privatization and the introduction of external capital from investment professionals
.
After privatization, Golden Voice will carry out business transformation and look for opportunities for a comeback
.
Nowadays, with the acceleration of the pace of life and work, as well as the influence of many factors such as poor air quality in cities and poor living habits, the incidence of various throat diseases is rising rapidly
.
Data show that the incidence of chronic pharyngitis in urban population in China accounts for 10%-12% of all pharyngeal diseases, and the incidence rate is as high as 60%-70%
.
Therefore, it is still very important to strengthen the R&D and production of drugs in the throat field, and the throat drug market still has a broad space for development
.
